We demonstrated through minigene-based analysis that splicing disruptions were induced by 28 out of 37 RAD51D variants (75.7%) originally identified in breast cancer cases and/or healthy controls of the BRIDGES cohort. This evidence concerns the gene RAD51D and breast carcinoma.